- We aspire to build a future of coexistence that promises happiness for all.
- Woosung Kee CEO and Vice Chairman, Celltrion
We aspire to build a future of coexistence that promises happiness for all.
Celltrion developed the world’s first antibody biosimilar “Remsima,” an achievement that shifted the paradigm of the global biopharmaceutical market previously dominated by a handful of multinational pharmaceutical giants and paved the way for the growth of the Korean pharmaceutical sector.
Over the years, many players in and outside of Korea have entered the biopharmaceutical market.
However, the path had been largely untrodden when Celltrion first sought to tread on it because of the massive capital and technical resources required and the slim chance of success. It was a lonely and challenging journey.
However, all of us at Celltrion shared a dream.
A dream to develop a biosimilar product to replace high-priced biopharmaceutical products for the benefit of patients across the world.
A dream to develop innovative new drugs and become a global biopharmaceutical leader.
We turned this dream into reality through thorough planning, deep conviction, and ceaseless efforts to overcome challenges.
We realized our dream by venturing into uncharted areas, and we will continue to tread our path toward the future.
We will do everything within our power to provide patients with more affordable and effective pharmaceutical products and promote health for all.
Your love and support will mean much to us in our journey to becoming a leading global biopharmaceutical company.
Woosung Kee CEO and Vice Chairman, Celltrion